arrow
S

Silvio Danese

IRCCS Ospedale San Raffaele
H指数:139
被引数:8.7万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Real-World Effectiveness and Safety of Upadacitinib in Patients With Crohn's Disease—A Multicentre Prospective Study From the Italian Group for the Study of Inflammatory Bowel Diseases (IG-IBD)

真实世界中乌帕替尼在克罗恩病患者中的有效性和安全性——一项来自意大利炎症性肠病研究组(IG-IBD)的多中心前瞻性研究

2026-09-110
PRE
Association Between Proton Pump Inhibitor Use and Gastric Neuroendocrine Neoplasms in Autoimmune Gastritis: A Real-World Propensity Score-Matched Study From the Autoimmune gastRitis Italian netwOrk Study grOup

质子泵抑制剂使用与自身免疫性胃炎中胃神经内分泌肿瘤的关系:来自自身免疫性胃炎意大利网络研究组的真实世界倾向性评分匹配研究

2026-09-070
PRE
Efficacy and safety of upadacitinib for Crohn’s disease in patients in East Asia: a post hoc analysis of randomized phase 3 studies

东亚太区克罗恩病患者中使用乌帕替尼的疗效与安全性:基于随机III期研究的回顾性分析

2026-08-300
OA
Comparative risk of postoperative complications in ulcerative colitis patients following preoperative advanced therapies: a network meta-analysis with meta-regression

溃疡性结肠炎患者术前接受高级疗法后术后并发症的对比风险:一项包含Meta回归的网络Meta分析

2026-08-080
PRE
Risk of serious infection, myocardial infarction, stroke, and thromboembolic events in patients in the United States with ulcerative colitis treated with tofacitinib compared with biologic treatments

与生物制剂治疗相比,美国溃疡性结肠炎患者使用托法替布治疗发生严重感染、心肌梗死、中风和血栓栓塞事件的风险

2026-07-280
OAAI
Corticosteroid-sparing effects of risankizumab versus ustekinumab in patients with moderately to severely active Crohn’s disease: post hoc results from the phase 3b SEQUENCE trial

瑞斯克珠单抗与优特克单抗在患有中重度活动性克罗恩病患者中的糖皮质激素节省效应:来自3b期SEQUENCE试验的事后分析结果

2026-07-210
OAAI
Comparative performance of intestinal ultrasound activity indices in pediatric ulcerative colitis: a prospective study

比较肠超声活动指数在儿童溃疡性结肠炎中的表现:一项前瞻性研究

2026-07-160
PRE
The Efficacy and Safety of Etrasimod in Mildly to Moderately Active Ulcerative Colitis: Results from the Phase 2 GLADIATOR Trial

轻度至中度活动性溃疡性结肠炎中Etrasimod的疗效与安全性:GLADIATOR 2期试验结果

2026-06-040
OAAI
Dynamic profiling in inflammatory Bowel disease: A manifesto for personalized care (vol 25, 104068, 2026)

炎症性肠病中的动态特征分析:个性化护理的宣言(卷 25,104068,2026)

2026-06-010
OAAI
The DICA endoscopic score and the CODA clinical score may predict the severity of acute diverticulitis and the risk of hospitalisation: results from an international multicentre prospective cohort study

DICA内镜评分和CODA临床评分可预测急性憩室炎的严重程度及住院风险:一项国际多中心前瞻性队列研究的结果

2026-05-050
OAAI
Mirikizumab is associated with rapid and sustained improvements in novel measures of bowel urgency in moderately-to-severely active ulcerative colitis: 28-week results from the LUCENT-URGE trial

米利克zumab与中度至重度活动性溃疡性结肠炎中肠道急迫性新指标快速且持续的改善相关:LUCENT-URGE试验的28周结果

2026-05-010
OA
Time to rethink washout periods in inflammatory bowel disease clinical trials: an international Delphi consensus

是时候重新思考炎症性肠病临床试验中的清洗期:一项国际德尔菲共识

2026-05-010
PRE